Public Profile

EMD Serono, Inc.

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is a leading biopharmaceutical company headquartered in the United States. Established in 2001, EMD Serono has made significant strides in the biotechnology sector, focusing on areas such as reproductive health, neurology, and immuno-oncology. With a strong presence in North America and Europe, the company is renowned for its innovative therapies, including cutting-edge treatments for infertility and multiple sclerosis. EMD Serono's commitment to research and development has positioned it as a key player in the biopharmaceutical industry, earning accolades for its contributions to patient care and scientific advancement. Through its unique product offerings and dedication to improving lives, EMD Serono continues to shape the future of healthcare.

DitchCarbon Score

How does EMD Serono, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

32

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

33

Industry Benchmark

EMD Serono, Inc.'s score of 32 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.

60%

Let us know if this data was useful to you

EMD Serono, Inc.'s reported carbon emissions

EMD Serono, Inc., headquartered in the US, currently does not provide specific carbon emissions data or reduction targets. Without available figures, it is challenging to assess their carbon footprint or climate commitments in detail. However, the company is expected to align with industry standards and best practices regarding climate action. As part of the broader pharmaceutical sector, EMD Serono is likely to engage in initiatives aimed at reducing greenhouse gas emissions and enhancing sustainability. Further information on their specific commitments or achievements in this area is not available at this time.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. EMD Serono, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for EMD Serono, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

EMD Serono, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Viatris

US
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Regeneron

US
Pharmaceutical Preparation Manufacturing
Updated 7 days ago

Genentech

US
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Novartis

CH
Pharmaceutical Preparation Manufacturing
Updated about 19 hours ago

Pfizer

US
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Glaxosmithkline

GB
Pharmaceutical Preparation Manufacturing
Updated about 14 hours ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers